000276228 001__ 276228
000276228 005__ 20241201014043.0
000276228 0247_ $$2doi$$a10.1002/ijc.34576
000276228 0247_ $$2pmid$$apmid:37226635
000276228 0247_ $$2ISSN$$a0020-7136
000276228 0247_ $$2ISSN$$a1097-0215
000276228 0247_ $$2altmetric$$aaltmetric:160846319
000276228 037__ $$aDKFZ-2023-01037
000276228 041__ $$aEnglish
000276228 082__ $$a610
000276228 1001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski-Fortner, Renée$$b0$$eFirst author$$udkfz
000276228 245__ $$aCharacterization of ovarian cancer survival by histotype and stage: A nationwide study in Norway.
000276228 260__ $$aBognor Regis$$bWiley-Liss$$c2023
000276228 3367_ $$2DRIVER$$aarticle
000276228 3367_ $$2DataCite$$aOutput Types/Journal article
000276228 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1732712780_22784
000276228 3367_ $$2BibTeX$$aARTICLE
000276228 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276228 3367_ $$00$$2EndNote$$aJournal Article
000276228 500__ $$a#EA:C020# / 2023 Sep 1;153(5):969-978
000276228 520__ $$aContemporary population-based data on ovarian cancer survival using current subtype classifications and by surgical status are sparse. We evaluated 1-, 3-, 5- and 7-year relative (and overall) survival, and excess hazards in patients with borderline tumors or invasive epithelial ovarian cancer diagnosed 2012 to 2021 in a nationwide registry-based cohort in Norway. Outcomes were evaluated by histotype, FIGO stage, cytoreduction surgery and residual disease. Overall survival was evaluated for non-epithelial ovarian cancer. Survival of women with borderline ovarian tumors was excellent (≥98.0% 7-year relative survival). Across all evaluated invasive epithelial ovarian cancer histotypes, 7-year relative survival for cases diagnosed with stages I or II disease was ≥78.3% (stage II high-grade serous). Survival for ovarian cancers diagnosed at stage ≥III differed substantially by histotype and time since diagnosis (eg, stage III, 5-year relative survival from 27.7% [carcinosarcomas] to 76.2% [endometrioid]). Overall survival for non-epithelial cases was good (91.8% 5-year overall survival). Women diagnosed with stage III or IV invasive epithelial ovarian cancer and with residual disease following cytoreduction surgery had substantially better survival than women not operated. These findings were robust to restriction to women with high reported functional status scores. Patterns for overall survival were similar to those for relative survival. We observed relatively good survival with early stage at diagnosis even for the high grade serous histotype. Survival for patients diagnosed at stage ≥III invasive epithelial ovarian cancer was poor for all but endometrioid disease. There remains an urgent need for strategies for risk reduction and earlier detection, together with effective targeted treatments.
000276228 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000276228 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000276228 650_7 $$2Other$$acytoreduction surgery
000276228 650_7 $$2Other$$ahistotype
000276228 650_7 $$2Other$$aovarian cancer
000276228 650_7 $$2Other$$astage
000276228 650_7 $$2Other$$asurvival
000276228 7001_ $$aTrewin-Nybråten, Cassia B$$b1
000276228 7001_ $$aPaulsen, Torbjørn$$b2
000276228 7001_ $$aLangseth, Hilde$$b3
000276228 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.34576$$gp. ijc.34576$$n5$$p969-978$$tInternational journal of cancer$$v153$$x0020-7136$$y2023
000276228 909CO $$ooai:inrepo02.dkfz.de:276228$$pVDB
000276228 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000276228 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000276228 9141_ $$y2023
000276228 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2022-11-25$$wger
000276228 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2022-11-25
000276228 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2022-11-25
000276228 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2022-11-25
000276228 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-21$$wger
000276228 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-21
000276228 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-21
000276228 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-21
000276228 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-21
000276228 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-21
000276228 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-10-21
000276228 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2022$$d2023-10-21
000276228 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2022$$d2023-10-21
000276228 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000276228 9200_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000276228 980__ $$ajournal
000276228 980__ $$aVDB
000276228 980__ $$aI:(DE-He78)C020-20160331
000276228 980__ $$aUNRESTRICTED